Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC -3.41%75 EV-to-FCF is 164.51 as of Aug. 08, 2026, which is 284% above its 10-year median of 42.85. GuruFocus rates PAHC with a GF Score™ of 75/100 and a GF Value™ of $29.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 569 Drug Manufacturers companies, Phibro Animal Health ranks worse than 91.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Phibro Animal Health's Enterprise Value is $2,101 Mil.
Phibro Animal Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $13 Mil. Therefore, Phibro Animal Health's EV-to-FCF for today is 164.51.
The historical rank and industry rank for Phibro Animal Health's EV-to-FCF or its related term are showing as below:
PAHC'
s EV-to-FCF Range Over the Past 10 Years
Min: -220.67 Med: 42.85 Max: 1618.43
Current: 164.51
During the past 13 years, the highest EV-to-FCF of Phibro Animal Health was 1618.43. The lowest was -220.67. And the median was 42.85.
PAHC's EV-to-FCF is ranked worse than 91.74% of 569
companies
in the Drug Manufacturers industry
Industry Median: 21.6
vs PAHC: 164.51
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Phibro Animal Health (NAS:PAHC) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Phibro Animal Health's PE Ratio (TTM) for today is calculated as:
Phibro Animal Health's share price for today is $34.26.
Phibro Animal Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Phibro Animal Health EV-to-FCF Related Terms
Phibro Animal Health EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's EV-to-FCF falls into.
Phibro Animal Health's current Enterprise Value is $2,101 Mil.
Phibro Animal Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phibro Animal Health (PAHC) has a EV-to-FCF of 164.51 as of Aug. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Phibro Animal Health and its competitors. This is 284% above median its historical median of 42.85. According to the industry distribution chart, Phibro Animal Health ranks #522 out of 569 companies in the Drug Manufacturers industry, placing it in the top 91.7%.
Is Phibro Animal Health's EV-to-FCF too high?
Phibro Animal Health's current EV-to-FCF of 164.51 is 284% above median its 10-year median of 42.85. The Drug Manufacturers industry median EV-to-FCF is 21.60. Phibro Animal Health's value of 164.51 is 661.6% above this industry median. Based on the distribution chart, Phibro Animal Health ranks #522 out of 569 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's EV-to-FCF compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #522 out of 569 companies for EV-to-FCF. This places Phibro Animal Health in the lower half of its industry. The industry median EV-to-FCF is 21.60. Phibro Animal Health's value of 164.51 is 661.6% above this benchmark. While the company's 10-year median is 42.85 vs. the industry median of 21.60, Phibro Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.60, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current EV-to-FCF of 164.51 is 661.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current EV-to-FCF is 164.51, which is 284% above median its own 10-year median of 42.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current EV-to-FCF is 164.51, which is 284% above median its 10-year median of 42.85 and 661.6% above the Drug Manufacturers industry median of 21.60. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current EV-to-FCF is 164.51 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
EV-to-FCF: 164.51 (284% above median its 10-year median of 42.85)
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 661.6% above the Drug Manufacturers median (#522 of 569)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
